134 related articles for article (PubMed ID: 8915713)
1. The clinical value of Cyfra 21-1 estimation for lung cancer patients.
Szturmowicz M; Sakowicz A; Rudzinski P; Zych J; Wiatr E; Zaleska J; Rowinska-Zakrzewska E
Int J Biol Markers; 1996; 11(3):172-7. PubMed ID: 8915713
[TBL] [Abstract][Full Text] [Related]
2. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of the value of determining levels of cytokeratin-19 fragments for diagnosis of lung cancer].
Szturmowicz M; Sakowicz A; Wiatr E; Zych J; Załeska J; Rudziński P; Rowińska-Zakrzewska E
Pneumonol Alergol Pol; 1995; 63(11-12):609-14. PubMed ID: 8616475
[TBL] [Abstract][Full Text] [Related]
5. Cyfra 21-1 as a marker of lung cancer.
Kinoshita M; Watanabe H; Ichiki M; Sumita S; Okubo Y; Matsunami M; Furuno H; Shiraishi T; Rikimaru T; Oizumi K
Kurume Med J; 1998; 45(1):7-9. PubMed ID: 9658744
[TBL] [Abstract][Full Text] [Related]
6. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
[TBL] [Abstract][Full Text] [Related]
7. Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection.
Yeh JJ; Liu FY; Hsu WH; Wang JJ; Ho ST; Kao A
Lung; 2002; 180(5):273-9. PubMed ID: 12489021
[TBL] [Abstract][Full Text] [Related]
8. CYFRA 21-1: an indicator of survival and therapeutic effect in lung cancer.
Takei Y; Minato K; Tsuchiya S; Takise A; Nakano H; Ezawa K; Fueki N; Hoshino H; Naruse I; Nomoto T; Makimoto T; Ishihara S; Saito R; Mori M
Oncology; 1997; 54(1):43-7. PubMed ID: 8978592
[TBL] [Abstract][Full Text] [Related]
9. Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levels.
Kashiwabara K; Nakamura H; Esaki T
Clin Chim Acta; 2000 Apr; 294(1-2):105-13. PubMed ID: 10727677
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study.
Ono A; Takahashi T; Mori K; Akamatsu H; Shukuya T; Taira T; Kenmotsu H; Naito T; Murakami H; Nakajima T; Endo M; Yamamoto N
BMC Cancer; 2013 Jul; 13():354. PubMed ID: 23879483
[TBL] [Abstract][Full Text] [Related]
11. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
[TBL] [Abstract][Full Text] [Related]
12. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.
Pujol JL; Grenier J; Daurès JP; Daver A; Pujol H; Michel FB
Cancer Res; 1993 Jan; 53(1):61-6. PubMed ID: 7677981
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer.
Szturmowicz M; Rudziński P; Kacprzak A; Langfort R; Bestry I; Broniarek-Samson B; Orłowski T
Pneumonol Alergol Pol; 2014; 82(5):422-9. PubMed ID: 25133810
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer.
Niklinski J; Furman M; Chyczewska E; Chyczewski L; Rogowski F; Laudanski J
Eur Respir J; 1995 Feb; 8(2):291-4. PubMed ID: 7538933
[TBL] [Abstract][Full Text] [Related]
15. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
Ebert W; Muley T
Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer.
Maeda Y; Segawa Y; Takigawa N; Takata I; Fujimoto N
Intern Med; 1996 Oct; 35(10):764-71. PubMed ID: 8933183
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer: results of a multicenter trial.
Bombardieri E; Seregni E; Bogni A; Ardit S; Belloli S; Busetto A; Caniello B; Castelli M; Cianetti A; Correale M
Int J Biol Markers; 1994; 9(2):89-95. PubMed ID: 7523547
[TBL] [Abstract][Full Text] [Related]
18. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group.
Rastel D; Ramaioli A; Cornillie F; Thirion B
Eur J Cancer; 1994; 30A(5):601-6. PubMed ID: 7521651
[TBL] [Abstract][Full Text] [Related]
19. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
20. Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer.
Niklinski J; Burzykowski T; Niklinska W; Laudanski J; Chyczewski L; Rapellino M; Furman M
Eur Respir J; 1998 Dec; 12(6):1424-8. PubMed ID: 9877503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
